Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.64 |
| ▸ | HTR1A | P08908 | 2/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.64 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.64 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.64 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.64 |
| ▸ | DRD1 | P21728 | 2/20 | 0.64 |
| ▸ | HTR2A | P28223 | 2/20 | 0.64 |
| ▸ | HTR2C | P28335 | 2/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.64 |
| ▸ | HRH1 | P35367 | 2/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.64 |
| ▸ | DRD3 | P35462 | 2/20 | 0.64 |
| ▸ | HTR2B | P41595 | 2/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.64 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL144624 | 0.92 | DRD2 (0.74) | DRD2LMNACHRM2HTR1AADRA2A | |
| SCHEMBL13440473 | 0.92 | DRD2 (0.74) | DRD2LMNACHRM2HTR1AADRA2A | |
| SCHEMBL8311 | 0.89 | DRD2 (1.00) | DRD2LMNACHRM2HTR1AADRA2A | |
| SCHEMBL29368614 | 0.89 | DRD2 (1.00) | DRD2LMNACHRM2HTR1AADRA2A | |
| Hydrochloric Acid SCHEMBL1943859 | 0.88 | DRD2 (0.97) | DRD2LMNACHRM2HTR1AADRA2A | |
| Hydrochloric Acid SCHEMBL8507 | 0.88 | DRD2 (0.97) | DRD2LMNACHRM2HTR1AADRA2A | |
| SCHEMBL3216890 | 0.87 | DRD2 (0.64) | DRD2LMNACHRM2HTR1AADRA2A | |
| SCHEMBL13528315 | 0.87 | DRD2 (0.64) | DRD2LMNACHRM2HTR1AADRA2A | |
| SCHEMBL3179409 | 0.87 | DRD2 (0.64) | DRD2LMNACHRM2HTR1AADRA2A | |
| SCHEMBL3179404 | 0.87 | DRD2 (0.64) | DRD2LMNACHRM2HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160361311-A1 | LIGANDS THAT TARGET HEPATITIS C VIRUS E2 PROTEIN | American University of Cairo (EG) | 2016-12-15 | — | — | US | disclosed |
| US-20160361311-A1 | LIGANDS THAT TARGET HEPATITIS C VIRUS E2 PROTEIN | American University of Cairo (EG) | 2016-12-15 | — | — | US | disclosed |
| US-20080241949-A1 | Process for preparing quetiapine fumarate | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2008-10-02 | — | — | US | disclosed |
| US-20080241949-A1 | Process for preparing quetiapine fumarate | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2008-10-02 | — | — | US | disclosed |
| WO-2006135544-A1 | SYNTHESIS OF 11-(4[-(2-HYDROXYETHOXY)ETHYL]-PIPERAZINYL)-DIBENZO[b,f][1,4]THIAZEPINE AND ITS FUMARATE SALT | CAMBREX CHARLES CITY, INC. (US) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361311-A1 | LIGANDS THAT TARGET HEPATITIS C VIRUS E2 PROTEIN | CD81, HAVCR2, CTRL | DRD2 2441/4885LMNA 4539/4885CHRM2 3630/4885 |
| US-20080241949-A1 | Process for preparing quetiapine fumarate | CYP3A5, CYP3A4, FH | DRD2 465/4885LMNA 2525/4885CHRM2 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.